
ZVRA Stock Forecast & Price Target
ZVRA Analyst Ratings
Bulls say
Zevra Therapeutics is a commercial-stage company with a promising late-stage pipeline that focuses on rare diseases. Its recent successful commercialization of miglustat, a treatment for Niemann-Pick disease type C (NPC), shows the company's potential to bring life-changing therapeutics to underserved patient populations. Furthermore, its ongoing clinical trials for other rare diseases, such as Urea Cycle Disorders and vEDS, offer potential for future growth and expansion. The company also has a strong safety profile and diversified revenue streams, mitigating potential risks such as payer pushback or competition from similar treatments.
Bears say
Zevra Therapeutics is a commercial-stage biotech company with one marketed product for the treatment of Niemann-Pick disease type C (NPC), a rare neurodegenerative disease. However, with only 73% of diagnosed patients currently being treated with the product, there is limited potential for revenue growth in the short term. Additionally, the company's late-stage pipeline and potential future earnings are uncertain, making it a risky investment for those seeking long-term gains.
This aggregate rating is based on analysts' research of Zevra Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ZVRA Analyst Forecast & Price Prediction
Start investing in ZVRA
Order type
Buy in
Order amount
Est. shares
0 shares